Literature DB >> 11269372

Comparison of antimicrobial susceptibility of Citrobacter freundii isolates in two different time periods.

J T Wang1, S C Chang, Y C Chen, K T Luh.   

Abstract

Citrobacter freundii was first identified in 1932, since then it has been reported to cause a variety of infections in aged, immunocompromised, and debilitated patients. With the use of broad-spectrum antibiotics, C. freundii has become increasingly resistant to antimicrobial agents. In order to determine the chronological changes in susceptibility and current susceptibility status of C. freundii, we compared the antimicrobial susceptibility of C. freundii in two different time periods, from 1987 to 1988 and from 1997 to 1998. In both time periods, 61 isolates of C. freundii were randomly selected for study from all clinical isolates at National Taiwan University Hospital. The minimum inhibitory concentrations and susceptible rates of 15 antimicrobial agents were compared, and it was found that most C. freundii isolates were resistant to anti-pseudomonal penicillins, first, second, and third generation cephalosporins, gentamicin, tobramycin, and aztreonam. The results indicate that the susceptible rates of C. freundii to aminoglycosides and ciprofloxacin decreased markedly during the period from 1987 to 1998. Cefepime, cefpirome, imipenem, and meropenem remained the most active agents against C. freundii.

Entities:  

Mesh:

Year:  2000        PMID: 11269372

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  15 in total

1.  Low-virulence Citrobacter species encode resistance to multiple antimicrobials.

Authors:  C Pepperell; J V Kus; M A Gardam; A Humar; L L Burrows
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Multidrug resistant citrobacter: an unusual cause of liver abscess.

Authors:  Prabhat Kumar; Soumik Ghosh; Deepak Rath; A K Gadpayle
Journal:  BMJ Case Rep       Date:  2013-04-22

3.  Citrobacter infections in a general hospital: characteristics and outcomes.

Authors:  G Samonis; D E Karageorgopoulos; D P Kofteridis; D K Matthaiou; V Sidiropoulou; S Maraki; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-08-06       Impact factor: 3.267

4.  Citrobacter freundii induced endocarditis in a yearling colt.

Authors:  Eleonora E A Guidi; Aurélie Thomas; Jean-Luc Cadoré; Agnès Benamou Smith
Journal:  Can Vet J       Date:  2016-07       Impact factor: 1.008

5.  Morphological alterations on Citrobacter freundii bacteria induced by erythrosine dye and laser light.

Authors:  Josmary R Silva; Gleidson Cardoso; Rafael R G Maciel; Nara C de Souza
Journal:  Lasers Med Sci       Date:  2013-08-24       Impact factor: 3.161

6.  Antibacterial activity of silver-doped hydroxyapatite nanoparticles against gram-positive and gram-negative bacteria.

Authors:  Carmen Steluta Ciobanu; Simona Liliana Iconaru; Phillippe Le Coustumer; Liliana Violeta Constantin; Daniela Predoi
Journal:  Nanoscale Res Lett       Date:  2012-06-21       Impact factor: 4.703

7.  Complete Genome Sequence of Citrobacter freundii Myophage Moon.

Authors:  Garrett B Edwards; Adrian J Luna; Adriana C Hernandez; Gabriel F Kuty Everett
Journal:  Genome Announc       Date:  2015-01-29

8.  Complete Genome Sequence of Citrobacter freundii Myophage Merlin.

Authors:  Kayla C LeSage; Emily C Hargrove; Jesse L Cahill; Eric S Rasche; Gabriel F Kuty Everett
Journal:  Genome Announc       Date:  2015-10-01

9.  Community-Acquired Pneumonia and Empyema Caused by Citrobacter koseri in an Immunocompetent Patient.

Authors:  Miguel Angel Ariza-Prota; Ana Pando-Sandoval; Marta García-Clemente; Ramón Fernández; Pere Casan
Journal:  Case Rep Pulmonol       Date:  2015-11-08

10.  An Analysis of the Effects of Vancomycin and/or Vancomycin-Resistant Citrobacter freundii Exposure on the Microbial Community Structure in Soil.

Authors:  Mariusz Cycoń; Sławomir Borymski; Kamila Orlewska; Tomasz J Wąsik; Zofia Piotrowska-Seget
Journal:  Front Microbiol       Date:  2016-06-28       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.